Umeclidinium (Incruse®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000586
Authors' recommendations: Umeclidinium (Incruse®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Bronchodilator Agents
  • Female
  • Male
  • Middle Aged
  • Forced Expiratory Volume
  • Muscarinic Antagonists
  • Pulmonary Disease, Chronic Obstructive
  • Quinuclidines
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
Contact Email:
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.